Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy.
Three years after measles, mumps, and rubella revaccination in 38 human immunodeficiency virus-infected children who had achieved immune recovery after antiretroviral therapy, the prevalence of protective antibody levels was 85% for measles, 61% for mumps, and 79% for rubella, compared with 88%, 84%, and 100%, respectively, 1 month after revaccination.
Aurpibul
Linda
L
Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Puthanakit
Thanyawee
T
Sirisanthana
Thira
T
Sirisanthana
Virat
V
D019380:Anti-HIV Agents / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000097:blood*; D023241:Antiretroviral Therapy, Highly Active; D002648:Child; D002675:Child, Preschool; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D008297:Male; D008457:Measles / Q000276:immunology*; D009107:Mumps / Q000276:immunology*; D012409:Rubella / Q000276:immunology*; D013997:Time Factors
D019380:Anti-HIV Agents; D000914:Antibodies, Viral